EVO — Evotec SE
$1.50-2.60%
Last close: · regular session
Last 60 sessions
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for EVO in the TickerWise workspace.
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
Company profile
- Sector: Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Country: DE
- Exchange: NASDAQ
- Employees: 4,766
- Website: https://www.evotec.com
Latest SEC filings for EVO
Latest EVO news
- Evotec Announces Chief Scientific Officer Transition Read article
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.